Sorafenib for the treatment of multiple myeloma

Multiple myeloma: the bone marrow microenvironment and its relation to treatment

(2016) S. W. Andrews et al.   BRITISH JOURNAL OF BIOMEDICAL SCIENCE

Myeloma today: Disease definitions and treatment advances

(2015) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

(2015) J. J. Shah et al.   BLOOD

Ixazomib for the treatment of multiple myeloma

(2015) Massimo Gentile et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).

(2015) Sagar Lonial et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple myeloma

(2015) Christoph Röllig et al.   LANCET

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

(2014) S. Bringhen et al.   BLOOD

Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis

(2014) A. Ramírez-Labrada et al.   Clinical & Translational Oncology

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

Multiple myeloma: a model for scientific and clinical progress

(2014) J. San Miguel   Hematology-American Society of Hematology Education Program

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434

(2014) Gordan Srkalovic et al.   Cancer Medicine

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

(2013) A. Larocca et al.   BLOOD

Potentin vitroandin vivoactivity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization

(2013) Josefina Udi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

(2013) D. Siegel et al.   HAEMATOLOGICA

Sorafenib in patients with refractory or recurrent multiple myeloma

(2013) Anna Yordanova et al.   HEMATOLOGICAL ONCOLOGY

Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies

(2013) Shaji K. Kumar et al.   INVESTIGATIONAL NEW DRUGS

Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma

(2013) Jesús F. San-Miguel et al.   JOURNAL OF CLINICAL ONCOLOGY

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

(2013) Joseph R. Mikhael et al.   MAYO CLINIC PROCEEDINGS

MEK inhibitors as a chemotherapeutic intervention in multiple myeloma

(2013) C Chang-Yew Leow et al.   Blood Cancer Journal

Multitargeted therapies for multiple myeloma

(2012) Pedram Kharaziha et al.   Autophagy

Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation

(2012) F. Langhauser et al.   BLOOD

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

(2012) Ravi Vij et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse Model

(2012) P. Kharaziha et al.   CANCER RESEARCH

Sorafenib in melanoma

(2012) Joanna Mangana et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

(2012) Andrzej J. Jakubowiak et al.   JOURNAL OF CLINICAL ONCOLOGY

Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

(2012) Sagar Lonial et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel therapies in MM: from the aspect of preclinical studies

(2011) Teru Hideshima et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

(2010) Gareth J Morgan et al.   LANCET

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

(2010) M Q Lacy et al.   LEUKEMIA

Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

(2009) V Ramakrishnan et al.   ONCOGENE

Clinical and biological significance of RAS mutations in multiple myeloma

(2008) W J Chng et al.   LEUKEMIA